Toxic Impurities in Active Pharmaceutical Ingredients 2019

Topics

• Handling trace analysis
• General Information about the limits for toxic impurities
• Structure and properties of NDEA
• Structure and properties of NDMA
• How are nitrosamines formed?
• Structure and properties of NMBA
• Some thoughts on other potential toxic impurities
• How did it get in sartans?

Who should Attend

• Research and Development Departments
• Quality Departments
• Validation Departments
• Regulatory Affairs Departments
• Everyone involved with New Product Selection
• Everyone involved with Analytical Method Development and Validation